Qyuns Therapeutics Sets Up Board Committee to Overhaul Executive Pay Oversight

An announcement from Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) is now available.

Qyuns Therapeutics has established a Remuneration and Appraisal Committee under its board of directors to standardize performance evaluation and pay management for directors and senior management. The committee is mandated to design assessment standards, conduct performance reviews and formulate or review remuneration policies and proposals, with accountability to the full board.

Under the new terms of reference, the committee will consist of at least three directors, the majority of whom must be independent non-executive directors, and will be chaired by an independent non-executive director. Members will be nominated by the board chair, a majority of independent non-executive directors or one-third of all directors and then elected by the board, aiming to strengthen corporate governance and oversight of executive compensation.

The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.

More about Qyuns Therapeutics Co., Ltd. Class H

Qyuns Therapeutics Co., Ltd. is a Hong Kong-listed biopharmaceutical company operating in the therapeutics sector. It is governed under the Company Law of the People’s Republic of China and the Hong Kong Listing Rules, and is refining its internal governance framework for directors and senior management in line with its articles of association and regulatory obligations.

Average Trading Volume: 241,118

Technical Sentiment Signal: Sell

Current Market Cap: HK$4.29B

For detailed information about 2509 stock, go to TipRanks’ Stock Analysis page.